[Comparative effectiveness of carbapenems and alternative antibiotics for the treatment of bacteraemia and/or urinary tract infectious disease by Enterobacteriaceae producing extended-spectrum β-lactamase]
Dong Ah Park, Jinnie Rhee, Na Rae Lee, Ji Jeong Park, Soo Kyung Son, Kyong Ran Peck, Su Yeun Moon, Eun-Jeong Joo, Jae-Ki Choi, Jae-Hoon Ko
Record ID 32016001008
Authors' recommendations: This study systematically reviewed the recently published evidence to evaluate the clinical effectiveness of carbapenems and other alternative antibiotics in treating bacteremia and urinary tract infection caused by ESBL-producing Enterobacteriaceae and analyzed the comparative clinical outcomes of those therapies using multi-center data in Korea. Although there was no clear evidence that superiority of carbapenem in empirical therapy, this study results suggest that carbapenem therapy is associated with a reduction of overall mortality when it is used as a definitive treatment in bacteremia caused by ESBL-producing Enterobacteriaceae, However, considering an increasing carbapenem resistance and non-inferiority of BL/BLIs use over carbapenems according to the study results, BL/BLIs can be used as alternatives for the treatment of patients with ESBL-positive Enterobacteriaceae bacteraemia. In patients with ESBL-positive Enterobacteriaceae urinary tract infection, the role of carbapenem and other antibiotics should be further evaluated for empirical and definitive treatment.
Project Status: Completed
Year Published: 2016
URL for published report: http://neca.re.kr/center/paper/report_view.jsp?boardNo=GA&seq=183&q=63706167653d3226666c61673d3126626f6172644e6f3d474126736561726368436f6c3d2673656172636856616c3d2673656172636853596561723d2673656172636845596561723d
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: South Korea
- Anti-Bacterial Agents
- Urinary Tract Infections
Organisation Name: National Evidence-based healthcare Collaborating Agency
Contact Address: National Evidence-based Healthcare Collaborating Agency (NECA), 3~5F Health and Welfare Social Administration B/D, 400 Neungdong-ro, Gwangjin-gu, Seoul, Korea.
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: National Evidence-based Healthcare Collaborating Agency (NECA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.